Industry Roundtable on Pharmaceutical Nanoformulations
Tech Session 2
Tech Session 2
|
Sponsored By:
|
|
The impact of nanotechnology on pharmaceuticals has been demonstrated in numerous ways, including
targeted cancer treatments, mRNA vaccines, intracellular siRNA delivery, antifungal therapies and other
treatments that leverage the power of nanoscale phenomena. Critical to the success of these
approaches is how the pharmaceutical formulation controls the size, shape, composition, stability,
biocompatibility and overall function of the nanomedicine. Even with careful design of these critical
attributes, success of the resulting nanomedicine is often hindered by challenges in the scale-up of
manufacture, difficulties in characterizing nanoformulations, quality control, and resulting challenges in
meeting regulatory requirements.
In this Industry Roundtable, a panel of experts will address five critical questions associated with
nanoformulation design, manufacturing, characterization and applications.
1. How are we exploiting the unique capabilities of nanoformulations in Pharma?
2. What challenges does manufacturing of nanoformulations present and how can they be
addressed?
3. What are the challenges of nanoformulations characterisation and how can they be addressed?
4. What are the regulatory requirements for nanoformulations characterisation and how are they
met?
5. How will nanoformulations make the greatest impact on medicine in the coming decade?
A panel member will take the lead on answering each question, followed by additional views and
commentary from the other panelists. The session is designed for significant interaction among the
panelists, as well as for questions and discussion by the session attendees.
targeted cancer treatments, mRNA vaccines, intracellular siRNA delivery, antifungal therapies and other
treatments that leverage the power of nanoscale phenomena. Critical to the success of these
approaches is how the pharmaceutical formulation controls the size, shape, composition, stability,
biocompatibility and overall function of the nanomedicine. Even with careful design of these critical
attributes, success of the resulting nanomedicine is often hindered by challenges in the scale-up of
manufacture, difficulties in characterizing nanoformulations, quality control, and resulting challenges in
meeting regulatory requirements.
In this Industry Roundtable, a panel of experts will address five critical questions associated with
nanoformulation design, manufacturing, characterization and applications.
1. How are we exploiting the unique capabilities of nanoformulations in Pharma?
2. What challenges does manufacturing of nanoformulations present and how can they be
addressed?
3. What are the challenges of nanoformulations characterisation and how can they be addressed?
4. What are the regulatory requirements for nanoformulations characterisation and how are they
met?
5. How will nanoformulations make the greatest impact on medicine in the coming decade?
A panel member will take the lead on answering each question, followed by additional views and
commentary from the other panelists. The session is designed for significant interaction among the
panelists, as well as for questions and discussion by the session attendees.
Marianne Ashford Astrazeneca Senior Principal Scientist |
Jeffrey Clogston National Cancer Institute Principal Scientist |
Laura Pala Oxford HighQ Business Development Scientist |
Franck Pavan V-nano General Manager |
